news

Changes of T Lymphocyte Subsets after CAR-T Cell Therapy and Its Clinical Significance

Aug 02, 2019

In tumor cell immunity, T cells play a central regulatory role. T cells are divided into several major subsets based on different

Know More

CAR-T therapy for kidney cancer shows early signs of efficacy in Chinese trial

Aug 02, 2019

A Chinese company has presented early clinical data on two CAR-T therapies in patients with kidney cancer

Know More

Clinical trials of CAR-T cells in China

Aug 02, 2019

Novel immunotherapeutic agents targeting tumor-site microenvironment are revolutionizing cancer therapy. Chimeric antigen receptor (CAR)-engineered

Know More

STEM Talent And China's Rise In The Race For CAR-T Immunotherapies

Aug 02, 2019

Timunity therapeutics is a biotech start-up company coming out of UPenn, with a cutting-edge technology in immunotherapy, it has recently attracted 135 million in funding for Series A. The start-up

Know More

China’s CAR-T Therapy Race

March 12, 2018

On March 12, 2018 the Chinese FDA (CFDA) approved the clinical trial application of LCAR-B38M CAR-T cell self-reinfusion preparation from Nanjing

Know More

United States vs. China: The CAR T-Cell Therapy Landscape & Comparative Analysis

March 12, 2018

Researchers from the Office of Clinical Evaluation of Biological Products, Center for Drug Evaluation, China Food and Drug Administration recently produced

Know More

Patient In China Free Of Leukemia After CAR T Cell Therapy

March 24, 2019

In China, a patient whose life was close to its end was completely cured of leukemia by stimulating the immune system using CAR T-cell therapy

Know More

Complete Remission Rate of 90%: China-based CAR-T Cell Therapy Achieves Breakthrough Clinical Trial Results

March 24, 2019

HANGZHOU, China, May 6, 2016 /PRNewswire/ -- At the 2016 Haematogenic Immunity Summit held in Hangzhou from April 22 to 24, 2016

Know More

CAR T Cells: Expanding into Multiple Myeloma

March 24, 2019

Before (left) and after (right) PET scans of a patient with multiple myeloma treated with BCMA-targeted CAR T cells.

Know More

CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update

March 24, 2019

Cellular therapies are a rapidly evolving approach to myeloma treatment, which bring a unique mechanism of action with the potential to overcome drug resistance and induce long-term remissions.

Know More

Multiple Myeloma Pipeline Filled With CAR T-Cell Therapies

March 24, 2019

The burgeoning pipeline of chimeric antigen receptor (CAR) T-cell therapies targeting B-cell maturation antigen (BCMA)

Know More

Sequential allogeneic and autologous CAR-T–cell therapy to treat an immune-compromised leukemic patient | Blood Advances

March 24, 2019

Chimeric antigen receptor (CAR) gene therapy is a breakthrough technology in treating refractory hematologic malignancies

Know More

USC-led advance in groundbreaking cancer treatment eliminates severe side effects

March 24, 2019

an advance in the groundbreaking cancer treatment known as CAR T-cell therapy appears to eliminate its severe side effects

Know More

BCMA-Targeting CAR T-Cell Therapy Effective in R/R Myeloma?

March 24, 2019

A phase I study out of China has provided additional evidence that chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA) leads to deep and durable responses in some patients

Know More

Joint New Zealand-China funding for CAR T-cell therapy research and development

May 21 2018

The Health Research Council (HRC) of New Zealand and the National Natural Science Foundation of China (NSFC) have announced a joint funding initiative to support further

Know More

CAR-T cell therapy saves cancer patients in China

May 21 2018

Instead of getting chemotherapy or waiting for hematopoietic stem cell transplantation, a 12-year-old girl from southwest China's Chongqing Municipality was saved by a non-conventional therapy

Know More

EFFICACY AND SAFETY OF CD22-DIRECTED CAR-T CELL THERAPY IN CHILDREN WITH REFRACTORY OR RELAPSED B ACUTE LYMPHOBLASTIC LEUKAEMIA

June 14 2018

Insights into CAR-T cell therapy presented at the 23rd Congress of the European Haematology Association, 14–17 June 2018, Stockholm

Know More

UniCAR Therapy and Terumo BCT Collaborate to Advance CAR T-Cell Therapies and Create a Shanghai, China Center of Excellence

June 14 2018

​LAKEWOOD, Colo., USA--October 9, 2018-- UniCAR-Therapy Bio-Medicine Technology Co. chose Terumo BCT and its cell expansion devices to automate its cell therapy

Know More

Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma

June 14 2018

​Multiple myeloma (MM) is one of the most common hematological malignancies. Developing an effective treatment strategy for refractory/relapsed

Know More

Present situation of China's CAR-T therapy

June 14 2018

​​Policy of CAR-T therapy in China 1.The declaration of CAR-T treatment in China has been accepted

Know More

J&J to enter Chinese CAR-T for myeloma into Phase Ib/II trial

June 14 2018

​​A Chinese CAR-T therapy that drew significant attention at last year’s American Society of Clinical Oncology meeting will enter a clinical trial in the US later this year.

Know More

Successful Clinical Results for a Novel CAR-T Cell Therapy: Is the Cure for Advanced Myeloma Patients within Our Reach

December 3, 2018

​​With regulatory approval of Chimeric Antigen Receptor (CAR) T-cell therapies for treating patients with aggressive blood cancer

Know More

Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen

16 July 2019

​​Division of Hematology, Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Antwerp, Belgium 2Laboratory of Experimental Hematology

Know More

Patient In China Free Of Leukemia After CAR T Cell Therapy

16 July 2019

​​In China, a patient whose life was close to its end was completely cured of leukemia by stimulating the immune system using CAR T-cell therapy

Know More

Anti-BCMA CAR T Cell Development Continues to Evolve for Multiple Myeloma

16 July 2019

​​Each of the many BCMA-targeted chimeric antigen receptor (CAR) T cells in development demonstrate a different efficacy and safety profile,

Know More

With some tweaks, CAR-T cancer therapy could be made safer — and more widely available — study suggests

16 July 2019

​​A novel approach to CAR-T cancer therapy promises to upend what has become a truism in medicine: that the treatment’s dramatic effect on tumors comes

Know More

The Latest Revolution in Cancer Treatment, Cell Therapy, is Moving Fast in China

July 29, 2018

​​The options available to cancer patients are changing rapidly thanks to developments in our understanding of the interplay between cancer and the immune system

Know More

CAR T Cells: Expanding into Multiple Myeloma

July 29, 2018

​​Results from two early-phase clinical trials suggest that a form of immunotherapy that uses genetically engineered immune cells may be highly effective

Know More

Ready to get started?

Get the financial help you need with the service you deserve. Lorem Ipsum is simply dummy text of the printing and typesetting industry.

Quick Loan Apply